Rice Research: Open Access
Open Access

CRISPR-Cas9; Genome Editing; Gene Editing; Disease Therapy; Cancer Therapy; Clinical Trials; Delivery Systems; Off-target Effects; Base Editing; Prime Editing; Agriculture; Ethics

Introduction

CRISPR-Cas9, a revolutionary tool, offers a comprehensive overview from its initial discovery to its current widespread application in genome editing. This technology has progressed significantly, spanning basic research, potential therapeutic tools, and diagnostic kits. Its remarkable versatility is a key highlight in recent studies[1].

Gene editing has been revolutionized by CRISPR-Cas9 this century, marking a significant advancement. This powerful tool's underlying mechanisms and broad applicability are crucial, particularly in addressing genetic diseases. The potential for CRISPR-Cas9 to reshape future medical treatments is increasingly evident[2].

Recent breakthroughs demonstrate CRISPR/Cas9's growing role in disease therapy. The technology is transitioning from laboratory research to practical therapeutic applications. Optimizing delivery methods and improving editing precision remain critical steps for successful treatment implementation[3].

CRISPR/Cas9 is also transforming agriculture, enabling precise genome editing in plants. This tool is vital for improving crops, enhancing their resilience, productivity, and nutritional value. Its diverse applications underscore its importance for global food security[4].

Significant progress in CRISPR-Cas9 research sees it moving from the lab into clinical trials. This gene-editing tool is now undergoing testing in human patients for various diseases. Ethical considerations and careful steps to ensure safety and efficacy are paramount in these pioneering clinical applications[5].

Effective cellular delivery of CRISPR/Cas9 is a critical focus for its therapeutic potential. Research reviews advanced delivery systems, including nanoparticles and viral vectors, discussing their benefits and limitations. Mastering efficient delivery is essential for unlocking the full capabilities of CRISPR[6].

A key challenge for CRISPR-Cas9 is minimizing unintended edits at non-target sites, known as off-target effects. Various strategies are being developed to enhance specificity and reduce these unwanted edits, which is crucial for ensuring safe and reliable therapeutic applications. Precision remains a primary goal[7].

The evolution of CRISPR technology includes next-generation tools like base editing and prime editing. These innovations enable highly precise changes to individual DNA bases without inducing double-strand breaks, thus expanding the scope of gene correction. These advanced tools offer even finer control over genetic modifications[8].

Human germline genome editing with CRISPR-Cas9 presents complex ethical and regulatory challenges. It raises significant questions regarding inheritable trait alterations and broader societal implications. Careful consideration and robust oversight are vital as this technology progresses[9].

CRISPR-Cas9 holds immense promise for revolutionizing cancer therapy. Strategies include targeting cancer-causing genes and boosting anti-tumor immunity, paving the way for more effective treatments. CRISPR offers a powerful new approach to combating various forms of cancer[10].

Description

CRISPR-Cas9 has fundamentally changed gene editing, providing a versatile tool that spans from its initial discovery to its widespread use across various fields. This technology's mechanistic understanding and broad applicability are highlighted in its revolutionary impact on genomic research [1, 2]. The ability to precisely modify genes offers unprecedented opportunities in both basic science and applied settings [1]. Scientists are leveraging CRISPR/Cas9 to improve a range of applications, including the development of advanced therapeutic strategies and sophisticated diagnostic tools [1]. This demonstrates a clear shift in how genetic interventions are conceived and executed, underscoring the technology's adaptable nature and significant potential [2].

A major focus for CRISPR/Cas9 is its role in disease therapy. Breakthroughs indicate a steady progression from research labs to real-world therapeutic applications, with ongoing efforts to refine delivery methods and enhance editing precision [3]. The technology holds substantial promise for addressing various genetic diseases, offering a new paradigm for medical treatments [2]. Beyond inherited conditions, CRISPR-Cas9 shows significant potential in cancer therapy. Researchers are exploring strategies to target cancer-causing genes and enhance anti-tumor immunity, which could lead to more effective treatments for various forms of cancer [10]. This represents a powerful new frontier in oncological interventions [10].

The journey of CRISPR-Cas9 from laboratory findings to clinical trials is marked by substantial progress. It is actively being tested in human patients for a range of diseases, highlighting a critical phase of its development [5]. However, several challenges must be overcome for safe and effective clinical implementation. One major hurdle is the efficient delivery of CRISPR/Cas9 into target cells. Advanced delivery systems, such as nanoparticles and viral vectors, are under intense review to optimize their advantages and mitigate their limitations [6]. Effective delivery is paramount for realizing the full therapeutic potential of CRISPR [6]. Another crucial aspect is minimizing off-target effects, which involve unintended edits at non-target genomic sites. Strategies are continually being developed to improve the specificity of CRISPR-Cas9, making it a more precise and safer tool for therapeutic applications [7].

The evolution of CRISPR technology continues with the emergence of next-generation tools like base editing and prime editing. These advanced technologies enable highly precise changes to individual DNA bases without creating double-strand breaks, significantly broadening the scope of gene correction capabilities [8]. These innovations offer even finer control over genetic modifications, pushing the boundaries of what is possible in genome editing [8]. Alongside these scientific advancements, human germline genome editing with CRISPR-Cas9 presents complex ethical and regulatory challenges. Discussions address fundamental questions about altering inheritable traits and the profound societal implications of such interventions [9]. Therefore, careful consideration and robust oversight are essential as this powerful technology continues to develop [9].

Beyond human health, CRISPR/Cas9 is significantly impacting agriculture. This precise genome editing tool is transforming crop improvement efforts, leading to plants that are more resilient, productive, and nutritious [4]. The discussion around its various applications truly showcases its potential to contribute to future global food security by enhancing crop traits and resistance [4].

Conclusion

CRISPR-Cas9 stands as a pivotal advancement in genome editing, evolving from its initial discovery to widespread application across diverse fields. It offers an unparalleled ability to precisely modify genetic material, opening new avenues in basic research, diagnostics, and therapeutic development [1, 2]. The technology is revolutionizing medical treatments, particularly for genetic diseases, and holds significant promise in the fight against cancer by targeting specific genes and enhancing immunity [2, 3, 10]. Beyond human health, CRISPR/Cas9 is transforming agriculture, enabling the creation of more resilient, productive, and nutritious crops, thereby contributing to global food security [4]. The advancement from laboratory settings to clinical trials is ongoing, with current applications being tested in human patients for various diseases [5]. However, critical challenges remain, including optimizing effective delivery systems into target cells and minimizing off-target effects for safer, more reliable therapeutic applications [6, 7]. The technology continues to evolve with innovations like base editing and prime editing, which offer even finer control over genetic modifications without inducing double-strand breaks [8]. The profound implications of CRISPR-Cas9, especially concerning human germline genome editing, necessitate careful ethical consideration and robust regulatory oversight [9]. This powerful tool's ongoing development promises further breakthroughs, cementing its role as a transformative force in biology and medicine.

References

1. Xinyi L, Yuyang H, Yongfeng S (2024) CRISPR-Cas9: a journey from mechanism to genome editing and beyond. J Biomed Sci 31:2.

   Indexed at, Google Scholar, CrossRef

2. Ashutosh T, Shwetanjali S, Rajbir S (2023) CRISPR-Cas9: A powerful tool for gene editing in the 21st century. J Biomed Res 38:1-13.

   Indexed at, Google Scholar, CrossRef

3. Jia-xin T, Ling-yu F, Li L (2023) Recent advances in CRISPR/Cas9-mediated gene editing for disease therapy. Cell Biosci 13:160.

   Indexed at, Google Scholar, CrossRef

4. Yubin J, Pengxiang Z, Yanzhi Y (2022) CRISPR/Cas9 genome editing in plants: A versatile tool for crop improvement. Genes 13:2231.

   Indexed at, Google Scholar, CrossRef

5. Daniel GSELF, Carina MBJMvdV, Joost S (2023) CRISPR-Cas9-based genome editing in clinical trials. Lancet Oncol 24:118-120.

   Indexed at, Google Scholar, CrossRef

6. Yuanyuan J, Fan W, Jing L (2022) Advanced CRISPR/Cas9 delivery systems for efficient genome editing. J Nanobiotechnology 20:334.

   Indexed at, Google Scholar, CrossRef

7. Huayan Z, Guodong L, Weilin X (2021) Minimizing off-target effects of CRISPR-Cas9 for precision genome editing. Cell Biosci 11:216.

   Indexed at, Google Scholar, CrossRef

8. Jiajie S, Yan C, Ling Z (2021) Base editing and prime editing: advanced technologies in CRISPR-Cas9 genome editing. Sig Transduct Target Ther 6:296.

   Indexed at, Google Scholar, CrossRef

9. Rui W, Bo-Tao L, Ying-Ying S (2020) Ethical and regulatory challenges of human germline genome editing using CRISPR-Cas9. Mol Ther Nucleic Acids 21:461-468.

   Indexed at, Google Scholar, CrossRef

10. Zhiyu C, Yujiao S, Lingling Z (2019) CRISPR-Cas9-mediated genome editing for cancer therapy. J Exp Clin Cancer Res 38:288.

    Indexed at, Google Scholar, CrossRef